Item 7.01 Regulation FD Disclosure.

On January 5, 2023, Terns Pharmaceuticals, Inc. (the "Company") issued a press release providing an update on the Company's pipeline and strategic priorities for 2023. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

Exhibit
No.                                       Description

99.1        Press Release issued by Terns Pharmaceuticals, Inc. on January 5, 2023.
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses